Details for Patent: 9,012,508

Which drugs does patent 9,012,508 protect, and when does it expire?

Patent 9,012,508 protects CALDOLOR and is included in one NDA.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 9,012,508

Title:	Administration of intravenous ibuprofen
Abstract:	An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia.
Inventor(s):	Pavliv; Leo (Cary, NC)
Assignee:	Cumberland Pharmaceuticals (Nashville, TN)
Application Number:	12/722,682
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,012,508

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-002	Jun 11, 2009		RX	Yes	Yes						MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-003	Jan 25, 2019		RX	Yes	Yes						MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY

International Family Members for US Patent 9,012,508

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010224063
Brazil	PI1006222
Canada	2754922
China	102413687
Denmark	2405748
European Patent Office	2405748
European Patent Office	3417708